1984
DOI: 10.1007/bf00445797
|View full text |Cite
|
Sign up to set email alerts
|

Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B)

Abstract: Three patients with a sporadic form of multiple endocrine neoplasia (MEN) IIb are presented. MEN IIb is the association of medullary carcinoma of the thyroid (MTC), pheochromocytoma and multiple mucosal neuromata. The age at diagnosis and primary therapy of MTC was relatively late (8, 16, 18 years) although thyroid enlargement (two cases), typical marfanoid habitus (two cases) or multiple mucosal neuromata (one case) had been evident since early childhood. The diagnosis was confirmed by measurements of tumour … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

1987
1987
2009
2009

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 15 publications
0
1
0
1
Order By: Relevance
“…However, no objective responses were observed. 92,93 Vandetanib (ZD 6474, Zactima; AstraZeneca, Wilmington, DE) is an oral TKI that targets the VEGF-2 and 3 receptors, RET (including the M918T RET mutation), and at higher concentrations, the epithelial growth factor (EGF) receptor. A recently completed open-label phase II trial investigated vandetanib activity in 30 MTC patients using a dose of 300 mg daily.…”
Section: Systemic Therapymentioning
confidence: 99%
“…However, no objective responses were observed. 92,93 Vandetanib (ZD 6474, Zactima; AstraZeneca, Wilmington, DE) is an oral TKI that targets the VEGF-2 and 3 receptors, RET (including the M918T RET mutation), and at higher concentrations, the epithelial growth factor (EGF) receptor. A recently completed open-label phase II trial investigated vandetanib activity in 30 MTC patients using a dose of 300 mg daily.…”
Section: Systemic Therapymentioning
confidence: 99%
“…trachealen Lymphgewebes beidseits (42,44) erforderlich. Ob allerdings eine radikale Neck-Dissektion bei bereits vorhandenen Lymphknotenmetastasen die Prognose gegenüber einem modifizierten Vorgehen verbessert, ist nicht sicher (5,8,11,13,17,29,42,44).…”
Section: Regionare Lymphknotenunclassified